Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA "consent agreement" with THA investigator

Executive Summary

Confirmed in May 4 letter from FDA Scientific Investigations Division Director Frances Kelsey, PhD, MD, to William Summers, MD. After receiving from Summers a "plan of continued compliance of clinical investigation" on April 10, Kelsey stated: "We consider your plan to represent a consent agreement with the agency, and to indicate our concurrence have signed it." Summers submitted the plan, outlining his intention to conduct investigations in accordance with FDA regs, to avoid being disqualified by the agency as an acceptable clinical investigator. The agency informed Summers of problems in the conduct and reporting of his study in early 1988. Published in the Nov. 13, 1986 New England Journal of Medicine, the study suggested dramatic improvement in patients taking tetrahydroaminoacridine (THA). . . .
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel